Dweck, Marc R.Bularga, AndaHahn, Rebecca T.Bing, RongLee, Kuan KenChapman, Andrew R.White, AudreyDi Salvo, GiovanniSade, Leyla ElifPearce, KeithNewby, David E.Popescu, Bogdan A.Donal, ErwanCosyns, BernardEdvardsen, ThorMills, Nicholas L.Haugaa, Kristina2021-05-162021-05-1620202047-2404https://watermark.silverchair.com/jeaa178.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAs4wggLKBgkqhkiG9w0BBwagggK7MIICtwIBADCCArAGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMWTja3Mw31eecYStXAgEQgIICgVJWs8-QPB7tJRP_k7h0ftCnjam_fN6j7zaZ_0hoFbk1McP13YeiH0BgZ2nKzXY2cBo0wKltTXQ_wzZDlIZXh9Nvfg-U3y4a2ELoeJ7TYPlGIeWbm8kUFNU_LCw-gY3b7fVBc2gpI4O4noVl4zQMI8oJWwO6nyHXgWwY5qLl7struEAXTYmI9qb71KeFdLuopk_xbMQJuOjv_NE00n1fbpUvRDoAAoSNU8sm8D2HoGyZRNS9Voobig8S1FkqyBHHwSHRJIPa9L-BaAEUiJjxqzmgkxgEQNhUuLUPFHHYoWm5UBZupJ_pHjmTH7eD5rA7nzuwr6cybyrmWcyefOajj38wpJf-VQlfujYifa9o0mEd6uIomk_uTBJ8R1rmEkl-LUbtVlaq-Q1BuBDcY7pIkP_7Dv21W4SCGH5XrTjeyElTxGlPG77nj-irj6icJgsftXa9jR20GF6Az5_KXtZhKSra4ICwN8AGjP1XKiQUPoTPK0pBVwHDtmUKwXQPw9YLPnRaLPur09JTIUIs39rtil_VKoEXc-lf6bPw5ra-99B8YtbnPqIC17AL5NKFRKbYRo54VUiuVjKIRRGi5_jdn0m_R2LDC51EzLfXS475vqyl1GLDUVD7kirOBChVcEfHWS1zey5UekjVF0AH09aEUB7C33WvKDgj6eJvtzxi2NfBT-ANRovtYRU5i1IeI2XalgQuAYPya1rqZqfuugD8cw6S5_Wjyl95a8ab_vJTnowa2tE7vgmre-5WdI_bRN6lL-Pfxwxy8LX03HFpPC5JJOazwCxgZIt5WFrivHujd2At6eRoynnWBMFR-ozswBslorg4It28EAIYNidTPr9g2UNRhttp://hdl.handle.net/11727/5859Aims To describe the cardiac abnormalities in patients with COVID-19 and identify the characteristics of patients who would benefit most from echocardiography. Methods and results In a prospective international survey, we captured echocardiography findings in patients with presumed or confirmed COVID-19 between 3 and 20 April 2020. Patient characteristics, indications, findings, and impact of echocardiography on management were recorded. Multivariable logistic regression identified predictors of echocardiographic abnormalities. A total of 1216 patients [62 (52-71) years, 70% male] from 69 countries across six continents were included. Overall, 667 (55%) patients had an abnormal echocardiogram. Left and right ventricular abnormalities were reported in 479 (39%) and 397 (33%) patients, respectively, with evidence of new myocardial infarction in 36 (3%), myocarditis in 35 (3%), and takotsubo cardiomyopathy in 19 (2%). Severe cardiac disease (severe ventricular dysfunction or tamponade) was observed in 182 (15%) patients. In those without pre-existing cardiac disease (n = 901), the echocardiogram was abnormal in 46%, and 13% had severe disease. Independent predictors of left and right ventricular abnormalities were distinct, including elevated natriuretic peptides [adjusted odds ratio (OR) 2.96, 95% confidence interval (CI) 1.75-5.05) and cardiac troponin (OR 1.69, 95% CI 1.13-2.53) for the former, and severity of COVID-19 symptoms (OR 3.19, 95% CI 1.73-6.10) for the latter. Echocardiography changed management in 33% of patients. Conclusion In this global survey, cardiac abnormalities were observed in half of all COVID-19 patients undergoing echocardiography. Abnormalities were often unheralded or severe, and imaging changed management in one-third of patients.enginfo:eu-repo/semantics/openAccessCOVID-19Echocardiographyarticle2199499580005667279000022-s2.0-85089289602